» Articles » PMID: 23082884

Multiple Resections for Patients with Glioblastoma: Prolonging Survival

Overview
Journal J Neurosurg
Specialty Neurosurgery
Date 2012 Oct 23
PMID 23082884
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Object: Glioblastoma is the most common and aggressive type of primary brain tumor in adults. These tumors recur regardless of intervention. This propensity to recur despite aggressive therapies has made many perceive that repeated resections have little utility. The goal of this study was to evaluate if patients who underwent repeat resections experienced improved survival as compared with patients with fewer numbers of resections, and whether the number of resections was an independent predictor of prolonged survival.

Methods: The records of adult patients who underwent surgery for an intracranial primary glioblastoma at an academic tertiary-care institution between 1997 and 2007 were retrospectively reviewed. Multivariate proportionalhazards regression analysis was used to identify an association between glioblastoma resection number and survival after controlling for factors known to be associated with survival, such as age, functional status, periventricular location, extent of resection, and adjuvant therapy. Survival as a function of time was plotted using the Kaplan-Meier method, and survival rates were compared using log-rank analysis.

Results: Five hundred seventy-eight patients with primary glioblastoma met the inclusion/exclusion criteria. At last follow-up, 354, 168, 41, and 15 patients underwent 1, 2, 3, or 4 resections, respectively. The median survival for patients who underwent 1, 2, 3, and 4 resections was 6.8, 15.5, 22.4, and 26.6 months (p < 0.05), respectively. In multivariate analysis, patients who underwent only 1 resection experienced shortened survival (relative risk [RR] 3.400, 95% CI 2.423-4.774; p < 0.0001) as compared with patients who underwent 2 (RR 0.688, 95% CI 0.525-0.898; p = 0.0006), 3 (RR 0.614, 95% CI 0.388-0.929; p = 0.02), or 4 (RR 0.600, 95% CI 0.238-0.853; p = 0.01) resections. These results were verified in a case-control evaluation, controlling for age, neurological function, periventricular tumor location, extent of resection, and adjuvant therapy. Patients who underwent 1, 2, or 3 resections had a median survival of 4.5, 16.2, and 24.4 months, respectively (p < 0.05). Additionally, the risk of infections or iatrogenic deficits did not increase with repeated resections in this patient population (p > 0.05).

Conclusions: Patients with glioblastoma will inevitably experience tumor recurrence. The present study shows that patients with recurrent glioblastoma can have improved survival with repeated resections. The findings of this study, however, may be limited by an intrinsic bias associated with patient selection. The authors attempted to minimize these biases by using strict inclusion criteria, multivariate analyses, and case-control evaluation.

Citing Articles

Impact of re-operation on progression-free survival in patients with recurrent GBM: Experience in a tertiary referral center.

Darwish H, Diab T, Kawtharani S, Barake M, Ali B, Ramadan N PLoS One. 2025; 20(1):e0317937.

PMID: 39888865 PMC: 11785342. DOI: 10.1371/journal.pone.0317937.


Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.

Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A BMC Med. 2024; 22(1):578.

PMID: 39639257 PMC: 11622503. DOI: 10.1186/s12916-024-03775-4.


Prospective longitudinal analysis of physiologic MRI-based tumor habitat predicts short-term patient outcomes in IDH-wildtype glioblastoma.

Moon H, Park J, Kim N, Kim N, Park S, Kim Y Neuro Oncol. 2024; 27(3):841-853.

PMID: 39450860 PMC: 11889713. DOI: 10.1093/neuonc/noae227.


Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Scoping Review.

Papacocea S, Vrinceanu D, Dumitru M, Manole F, Serboiu C, Papacocea M Int J Mol Sci. 2024; 25(17).

PMID: 39273661 PMC: 11395592. DOI: 10.3390/ijms25179714.


Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma.

Ledford A, Rodriguez A, Lipinski L, Abad A, Fenstermaker R, Edenfield J Sci Rep. 2024; 14(1):19474.

PMID: 39198514 PMC: 11358395. DOI: 10.1038/s41598-024-68801-0.


References
1.
Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

2.
Hart M, Grant R, Garside R, Rogers G, Somerville M, Stein K . Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2008; (4):CD007415. DOI: 10.1002/14651858.CD007415. View

3.
Chaichana K, Garzon-Muvdi T, Parker S, Weingart J, Olivi A, Bennett R . Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2010; 18(1):239-45. PMC: 4612568. DOI: 10.1245/s10434-010-1242-6. View

4.
Keles G, Anderson B, Berger M . The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999; 52(4):371-9. DOI: 10.1016/s0090-3019(99)00103-2. View

5.
Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View